DEPRESSION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ENHANCEMENT OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AS AN EXPRESSION OF LOCAL INFLAMMATION

被引:1
|
作者
BROMMER, EJP [1 ]
DOOIJEWAARD, G [1 ]
DIJKMANS, BAC [1 ]
BREEDVELD, FC [1 ]
机构
[1] LEIDEN UNIV HOSP,DEPT RHEUMATOL,2333 AA LEIDEN,NETHERLANDS
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inflammatory processes are accompanied by extravascular deposition and breakdown of fibrin. We measured fibrinolytic parameters in synovial fluid (SF) and in plasma of 36 patients with rheumatoid arthritis (RA). As a control, SF of 13 patients with blunt knee trauma, and plasma of 17 healthy volunteers were studied. In RA patients, extravascular t-PA mediated plasminogen activation was depressed: mean SF tissue-type plasminogen activator (t-PA:Ag) concentration (2.1 +/- 1.6 ng/ml) was fourfold lower, and plasminogen activator inhibitor (PAI) activity (284 +/- 212%) four-fold higher than the plasma values of the same patients or of healthy donors. In contrast, u-PA related plasminogen activation was strongly enhanced: urokinase-type plasminogen activator (u-PA) antigen (23.1 +/- 12.4 ng/ml) was more than four-fold higher, single-chain u-PA (scu-PA) (5.3 +/- 1.9 ng/ml) three-fold higher than in plasma of the same patients or of healthy donors, and active two-chain u-PA (tcu-PA) was detected in 14 of the 36 SF samples of RA patients. All of these changes in extravascular fibrinolytic parameters correspond with those induced by inflammatory mediators in cell cultures. In joint effusions of patients with a blunt knee trauma, the effects were intermediate: u-PA related parameters showed moderate changes in the same direction as in arthritis; t-PA antigen was also decreased. The only exception was that PAI was not increased. We conclude that the findings in traumatic effusions reflect transient effects as a reaction to trauma. In joint inflammation, the depressed t-PA mediated plasminogen activation, although more than compensated by the enhanced u-PA mediated plasminogen activation, results in protraction of fibrin removal. Besides, the enhanced u-PA activation might lead to proteolytic damage of the cartilage.
引用
收藏
页码:180 / 184
页数:5
相关论文
共 50 条
  • [1] ON THE REVERSIBLE INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND WITH UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    LIJNEN, HR
    VANHOEF, B
    COLLEN, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (07) : 4041 - 4044
  • [2] GENE INACTIVATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN MICE
    CARMELIET, P
    SCHOONJANS, L
    STASSEN, JM
    KIECKENS, L
    VANNUFFELEN, A
    DEMOL, M
    COLLEN, D
    MULLIGAN, R
    [J]. THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 764 - 764
  • [3] CONSTRUCTION AND EXPRESSION OF HYBRID PLASMINOGEN ACTIVATORS PREPARED FROM TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENES
    LEE, SG
    KALYAN, N
    WILHELM, J
    HUM, WT
    RAPPAPORT, R
    CHENG, SM
    DHEER, S
    URBANO, C
    HARTZELL, RW
    RONCHETTIBLUME, M
    LEVNER, M
    HUNG, PP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1988, 263 (06) : 2917 - 2924
  • [4] BIOLOGICAL EFFECTS OF INACTIVATION OF THE GENES FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN MICE
    CARMELIET, P
    SCHOONJANS, L
    KIECKENS, L
    STASSEN, JM
    BRONSON, R
    COLLEN, D
    MULLIGAN, R
    [J]. FIBRINOLYSIS, 1993, 7 : 27 - 28
  • [5] BIOLOGICAL EFFECTS OF DISRUPTION OF THE TISSUE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENES IN MICE
    CARMELIET, P
    BOUCHE, A
    DECLERCQ, C
    JANSSEN, S
    POLLEFEYT, S
    WYNS, S
    MULLIGAN, RC
    COLLEN, D
    [J]. ATHEROSCLEROSIS III: RECENT ADVANCES IN ATHEROSCLEROSIS RESEARCH: THE THIRD SARATOGA INTERNATIONAL CONFERENCE ON ATHEROSCLEROSIS IN NEKOMA, 1995, 748 : 367 - 382
  • [6] POTENTIATION BY LYS-PLASMINOGEN OF CLOT LYSIS BY SINGLE OR 2 CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR OR TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    WATAHIKI, Y
    SCULLY, MF
    ELLIS, V
    KAKKAR, VV
    [J]. THROMBOSIS AND HAEMOSTASIS, 1989, 61 (03) : 502 - 506
  • [7] POTENTIATION BY LYS-PLASMINOGEN OF CLOT LYSIS BY SINGLE OR 2 CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR OR TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    WATAHIKI, Y
    SCULLY, MF
    ELLIS, V
    KAKKAR, VV
    [J]. THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 83 - 83
  • [8] KINETICS OF INHIBITION OF TISSUE-TYPE AND UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 AND TYPE-2
    THORSEN, S
    PHILIPS, M
    SELMER, J
    LECANDER, I
    ASTEDT, B
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 175 (01): : 33 - 39
  • [9] EXPRESSION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR IN COLON-DISEASE
    MISELJIC, S
    GALANDIUK, S
    MYERS, SD
    WITTLIFF, JL
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1995, 9 (06) : 413 - 417
  • [10] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND MALIGNANCY
    DUFFY, MJ
    [J]. FIBRINOLYSIS, 1993, 7 (05) : 295 - 302